366 related articles for article (PubMed ID: 22897848)
1. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis.
Sander S; Calado DP; Srinivasan L; Köchert K; Zhang B; Rosolowski M; Rodig SJ; Holzmann K; Stilgenbauer S; Siebert R; Bullinger L; Rajewsky K
Cancer Cell; 2012 Aug; 22(2):167-79. PubMed ID: 22897848
[TBL] [Abstract][Full Text] [Related]
2. Burkitt lymphomagenesis linked to MYC plus PI3K in germinal center B cells.
Sander S; Rajewsky K
Oncotarget; 2012 Oct; 3(10):1066-7. PubMed ID: 23164662
[No Abstract] [Full Text] [Related]
3. Nuclear FOXO1 promotes lymphomagenesis in germinal center B cells.
Kabrani E; Chu VT; Tasouri E; Sommermann T; Baßler K; Ulas T; Zenz T; Bullinger L; Schultze JL; Rajewsky K; Sander S
Blood; 2018 Dec; 132(25):2670-2683. PubMed ID: 30333121
[TBL] [Abstract][Full Text] [Related]
4. Burkitt lymphoma: much more than MYC.
Dominguez-Sola D; Dalla-Favera R
Cancer Cell; 2012 Aug; 22(2):141-2. PubMed ID: 22897844
[TBL] [Abstract][Full Text] [Related]
5. Concomitant reduction of c-Myc expression and PI3K/AKT/mTOR signaling by quercetin induces a strong cytotoxic effect against Burkitt's lymphoma.
Granato M; Rizzello C; Romeo MA; Yadav S; Santarelli R; D'Orazi G; Faggioni A; Cirone M
Int J Biochem Cell Biol; 2016 Oct; 79():393-400. PubMed ID: 27620077
[TBL] [Abstract][Full Text] [Related]
6. Myc suppression of Nfkb2 accelerates lymphomagenesis.
Keller U; Huber J; Nilsson JA; Fallahi M; Hall MA; Peschel C; Cleveland JL
BMC Cancer; 2010 Jul; 10():348. PubMed ID: 20598117
[TBL] [Abstract][Full Text] [Related]
7. BI6727, a polo-like kinase 1 inhibitor with promising efficacy on Burkitt lymphoma cells.
Chen E; Pei R
J Int Med Res; 2020 May; 48(5):300060520926093. PubMed ID: 32468878
[TBL] [Abstract][Full Text] [Related]
8. BCL-W has a fundamental role in B cell survival and lymphomagenesis.
Adams CM; Kim AS; Mitra R; Choi JK; Gong JZ; Eischen CM
J Clin Invest; 2017 Feb; 127(2):635-650. PubMed ID: 28094768
[TBL] [Abstract][Full Text] [Related]
9. c-Myc overexpression promotes a germinal center-like program in Burkitt's lymphoma.
Scheller H; Tobollik S; Kutzera A; Eder M; Unterlehberg J; Pfeil I; Jungnickel B
Oncogene; 2010 Feb; 29(6):888-97. PubMed ID: 19881537
[TBL] [Abstract][Full Text] [Related]
10. Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis.
Garrison SP; Jeffers JR; Yang C; Nilsson JA; Hall MA; Rehg JE; Yue W; Yu J; Zhang L; Onciu M; Sample JT; Cleveland JL; Zambetti GP
Mol Cell Biol; 2008 Sep; 28(17):5391-402. PubMed ID: 18573879
[TBL] [Abstract][Full Text] [Related]
11. Physiological levels of the PTEN-PI3K-AKT axis activity are required for maintenance of Burkitt lymphoma.
Gehringer F; Weissinger SE; Möller P; Wirth T; Ushmorov A
Leukemia; 2020 Mar; 34(3):857-871. PubMed ID: 31719683
[TBL] [Abstract][Full Text] [Related]
12. Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.
Ni F; Huang X; Chen Z; Qian W; Tong X
Sci Rep; 2018 Feb; 8(1):3317. PubMed ID: 29463831
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA 28 controls cell proliferation and is down-regulated in B-cell lymphomas.
Schneider C; Setty M; Holmes AB; Maute RL; Leslie CS; Mussolin L; Rosolen A; Dalla-Favera R; Basso K
Proc Natl Acad Sci U S A; 2014 Jun; 111(22):8185-90. PubMed ID: 24843176
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma.
Giulino-Roth L; van Besien HJ; Dalton T; Totonchy JE; Rodina A; Taldone T; Bolaender A; Erdjument-Bromage H; Sadek J; Chadburn A; Barth MJ; Dela Cruz FS; Rainey A; Kung AL; Chiosis G; Cesarman E
Mol Cancer Ther; 2017 Sep; 16(9):1779-1790. PubMed ID: 28619753
[TBL] [Abstract][Full Text] [Related]
15. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
[TBL] [Abstract][Full Text] [Related]
16. The IKK2/NF-{kappa}B pathway suppresses MYC-induced lymphomagenesis.
Klapproth K; Sander S; Marinkovic D; Baumann B; Wirth T
Blood; 2009 Sep; 114(12):2448-58. PubMed ID: 19628709
[TBL] [Abstract][Full Text] [Related]
17. Forward and reverse changes in Ig/myc translocation carrying tumors.
Klein G
Princess Takamatsu Symp; 1989; 20():135-42. PubMed ID: 2562178
[TBL] [Abstract][Full Text] [Related]
18. NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma.
Han SS; Yun H; Son DJ; Tompkins VS; Peng L; Chung ST; Kim JS; Park ES; Janz S
Mol Cancer; 2010 Apr; 9():97. PubMed ID: 20433747
[TBL] [Abstract][Full Text] [Related]
19. Retinoic acid induces persistent, RARalpha-mediated anti-proliferative responses in Epstein-Barr virus-immortalized b lymphoblasts carrying an activated C-MYC oncogene but not in Burkitt's lymphoma cell lines.
Cariati R; Zancai P; Quaia M; Cutrona G; Giannini F; Rizzo S; Boiocchi M; Dolcetti R
Int J Cancer; 2000 May; 86(3):375-84. PubMed ID: 10760826
[TBL] [Abstract][Full Text] [Related]
20. Deregulated expression of the Myc cellular oncogene drives development of mouse "Burkitt-like" lymphomas from naive B cells.
Zhu D; Qi CF; Morse HC; Janz S; Stevenson FK
Blood; 2005 Mar; 105(5):2135-7. PubMed ID: 15522957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
